Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation
13
Issued Date
2022-04-01
Resource Type
ISSN
13835769
eISSN
18730329
Scopus ID
2-s2.0-85122484771
Pubmed ID
34896614
Journal Title
Parasitology International
Volume
87
Rights Holder(s)
SCOPUS
Bibliographic Citation
Parasitology International Vol.87 (2022)
Suggested Citation
Tachibana M., Takashima E., Morita M., Sattabongkot J., Ishino T., Culleton R., Torii M., Tsuboi T. Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation. Parasitology International Vol.87 (2022). doi:10.1016/j.parint.2021.102525 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85006
Title
Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation
Author's Affiliation
Other Contributor(s)
Abstract
Existing control measures have significantly reduced malaria morbidity and mortality in the last two decades, although these reductions are now stalling. Significant efforts have been undertaken to develop malaria vaccines. Recently, extensive progress in malaria vaccine development has been made for Plasmodium falciparum. To date, only the RTS,S/AS01 vaccine has been tested in Phase 3 clinical trials and is now under implementation, despite modest efficacy. Therefore, the development of a malaria transmission-blocking vaccine (TBV) will be essential for malaria elimination. Only a limited number of TBVs have reached pre-clinical or clinical development with several major challenges impeding their development, including low immunogenicity in humans. TBV development efforts against P. vivax, the second major cause of malaria morbidity, lag far behind those for P. falciparum. In this review we summarize the latest progress, challenges and innovations in P. vivax TBV research and discuss how to accelerate its development.